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Currently, surgical resection is the treatment strategy oﬀering the best long-term outcomes in patients with hepatocellular
carcinoma (HCC). Especially for advanced HCC, surgical resection is the only strategy that is potentially curative, and the
indications for surgical resection have expanded concomitantly with the technical advances in hepatectomy. A major problem
is the high recurrence rate even after curative resection, especially in the remnant liver. Although repeat hepatectomy may prolong
survival, the suitability may be limited due to multiple tumor recurrence or background liver cirrhosis. Multimodality approaches
combining other local ablation or systemic therapy may help improve the prognosis. On the other hand, minimally invasive,
or laparoscopic, hepatectomy has become popular over the last decade. Although the short-term safety and feasibility has been
established, the long-term outcomes have not yet been adequately evaluated. Liver transplantation for HCC is also a possible
option. Given the current situation of donor shortage, however, other local treatments should be considered as the ﬁrst choice as
long as liver function is maintained. Non-transplant treatment as a bridge to transplantation also helps in decreasing the risk of
tumor progression or death during the waiting period. The optimal timing for transplantation after HCC recurrence remains to
be investigated.
1.Introduction
Surgical resection is currently the standard option and treat-
ment of ﬁrst choice for hepatocellular carcinoma (HCC),
given appropriate patient selection. The safety of surgical
resection has been established over the last few decades,
and the mortality rate after hepatic resection in experienced
centers is less than 5%. The indications for surgical resection
have expanded even to advanced HCCs, as complicated
hepatic resection can be safely performed owing to advances
in the surgical techniques. At the same time, the minimally
invasive approach, namely, laparoscopic hepatectomy, has
also come to be increasingly advocated over the last decade.
The safety and feasibility of laparoscopic hepatectomy after
the learning curve period has been established in high-
volume institutions, and the indications have been expanded
frompartial resectionof benign tumorstomajorresection of
malignant tumors, including HCCs. In this paper, the roles
of aggressive hepatic resection for advanced HCC, the role of
the recently advocated minimally invasive hepatectomy, the
role of preoperative and postoperative adjuvant treatments,
and the importance of a multimodality approach, includ-
ing local ablation therapy, transarterial chemoembolization
(TACE), and liver transplantation, are described.
2. Expansionof the Indicationsfor
SurgicalResection
Curative surgical resection is currently the only strategy for
achieving a potentially satisfactory long-term outcome in
patients with HCC and should, therefore, be the treatment
of ﬁrst choice as long as the tumor is judged to be resectable.
Here, the term “resectability” is subjective and its deﬁnition
varies according to the surgeons’ skill. Several criteria to
decide the indication for surgical resection based on the liver
function and tumor status have been proposed. The method
adopted for preoperative evaluation of liver function, which
woulddeterminetheextentofresectionoftheliver,mayvary2 International Journal of Hepatology
among districts and institutions. In most Western countries,
the presence/absence of portal hypertension is emphasized
as an important criterion, which is estimated along with the
Child-Pugh class, and is diagnosed based on the ﬁndings
in hepatic venous pressure gradient, radiological images of
splenomegaly and abdominal collaterals, thrombocytopenia
(platelets <100,000/mm3), and presence of esophagogastric
varices [1, 2]. One of the classical staging systems under
the Barcelona Clinic Liver Cancer (BCLC) criteria included
these criteria for the selection of appropriate treatments and
recommended hepatic resection only for patients with a
solitary HCC without portal hypertension [3]. Furthermore,
this criterion is also included in the guideline for the
treatment of HCC established by the American Association
for the Study of Liver Diseases and European Association
for the Study of the Liver [2, 4]. In contrast, several studies
reported the experiences of resection of multinodular HCCs
or HCCs with portal hypertension yielding survival beneﬁts,
especially in patients where the background liver cirrhosis
was classiﬁed as Child-Pugh class A [5, 6].
On the other hand, in Asian countries indocyanine
green retention at 15 minutes (ICG-R15) is used for patient
selection [3, 7, 8]. ICG-R15 is included in the preoperative
evaluation of liver damage, along with determination of
the presence/absence of ascites, serum bilirubin, serum
albumin, and prothrombin time [9]. Recently published
Japanese evidence-based clinical guidelines for the diagnosis
and treatment of HCC propose surgical resection as the
treatment of ﬁrst choice for HCC patients with 3 or fewer
nodules of any size categorized into liver damage of A or
B[ 10]. This guideline recommend either surgical resection
or local ablation therapy for early HCC [10]; however, it
still remains under debate as to which of the two modalities
might be more appropriate. Two randomized controlled tri-
als(RCTs)comparingsurgicalresectionandablationtherapy
for small HCCs have been reported, and both yielded similar
therapeutic results [11, 12]. However, there were critical
ﬂaws in both studies, including an insuﬃcient number
of patients, imbalance in the background characteristics,
and high conversion rates; therefore, the results of these
two RCTs are invalid [13]. In 2010, Huang et al. reported
the results of an RCT of hepatectomy and radiofrequency
ablation (RFA) for patients with HCC fulﬁlling the Milan
criteria (single tumor ≤5cm, or two or three tumors with
none >3cm) [14] and categorized as Child-Pugh A or B.
Each of the hepatectomy and RFA groups included 115
patients.Althoughthetumorsizewaslargerinpatientsinthe
hepatectomy group, the prognosis was signiﬁcantly better in
this group than that in the RFA group (5-year survival rate:
76% versus 55%). Further analyses by subgroup in patients
with solitary HCC measuring 3cm or less, solitary HCC
measuring 3 to 5cm, multinodular HCCs, or HCC patients
withseverelivercirrhosisshowedsigniﬁcantlybettersurvival
in the patients undergoing hepatectomy in all subgroups
[15].
For more advanced HCCs, such as huge tumors mea-
suring more than 10cm in diameter, tumors associated with
macroscopic vascular invasion, or tumors with extrahepatic
metastases, surgical resection is advocated, because no other
treatments such as local ablation, systemic chemotherapy, or
liver transplantation are eﬀective. Portal vein embolization
(PVE), which was originally proposed as a strategy to
decrease the risk of hepatic failure after extended hepate-
ctomy for hilar cholangiocarcinoma [16], also has a role
in increasing the patient suitability for hepatic resection in
patients with HCC [17]. Although the regenerative capacity
of the cirrhotic liver may be poor, the combination of
PVE with TACE [18, 19], further combined with hepatic
vein embolization, may help in increasing the patient suit-
ability for hepatectomy [20]. Although studies encouraging
aggressive surgery for advanced HCCs, as described below,
were all retrospective in nature and showed good results in
selected patients, surgery should be advocated if the safety
is guaranteed by a low mortality and morbidity, because no
other treatment has been demonstrated to be potentially as
eﬀective.
2.1. Large HCCs. Several studies have reported the short-
and long-term outcomes of resection of extremely large
(>10cm in diameter) HCCs [21–24]. In these studies, 40 to
166 patients with HCC tumors measuring 10cm or more
in diameter were evaluated. Although relatively extensive
hepatic resection was required, associated with an increased
blood loss, the postoperative morbidity and mortality were
comparable with those of hepatectomy for smaller HCCs.
The mortality and 5-year overall survival rates were 2–
3.3% and 28–33%, respectively. Multiple tumors, vascular
invasion, and impaired liver function were found to be
predictors of poor survival. The safety and survival beneﬁts
shown in selected patients in these studies may justify
aggressive resection for large HCCs.
Large HCCs should be treated by surgical resection as
long as the liver function is maintained within a satisfactory
range.Recently,nonalcoholicfattyliverdisease(NAFLD)has
been increasingly identiﬁed as a cause of HCC. Paradis et al.
[25] compared the pathologic features of HCCs associated
with metabolic syndrome or arising in a background of
cryptogenic cirrhosis with those arising in a background of
chronic liver disease. The former are larger in size, more
frequently well diﬀerentiated and the background liver is
less ﬁbrotic. Therefore, the opportunity to resect indications
for resection in patients with large HCCs is expected to
increase.
2.2. HCCs with Macroscopic Vascular Invasion. Presence/
absence of macroscopic vascular invasion is one of the
strongest predictors of the prognosis in patients with HCC.
HCCs tend to invade adjacent venous tributaries, which is
associated with an increased risk of intrahepatic or extra-
hepatic metastases [26–28]. Resection of HCCs with macro-
scopic vascular invasion or tumor thrombi is technically
challenging and has been considered to yield limited survival
beneﬁt. However, the prognosis of HCCs with vascular
invasion is even more dismal if they are left untreated.
The median survival of untreated HCC patients with portal
venous invasion is only 2.7 months [29]. Surgical resection
leads to better survival outcomes than nonsurgical treatment
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beneﬁt of surgical resection in HCC patients with portal
venous invasion of the main trunk (Vp4 [9]) or of a ﬁrst-
order branch (right or left main trunk, Vp3) as compared
with that in HCC patients with portal venous invasion of the
secondary tributaries (Vp2) or further peripheral tributaries
(Vp1)oftheportalvein,andresectionforHCCswithVp3or
Vp4 is not recommended [31, 32]. On the other hand, some
authors have advocated aggressive resection even for HCCs
with Vp3 or Vp4, reporting 5-year survival rates ranging
from 10.9% to 42% [33–38]. Minagawa et al. previously
reported the outcomes of 18 selected HCC patients with Vp3
or Vp4 treated by preoperative TACE followed by anatomical
hepatic resection and reported a 5-year survival rate of 42%
[34]. Based on the results of multivariate analyses, they
proposed selection criteria for TACE followed by resection as
no more than two nodules, a nonoccluded portal vein trunk,
and an ICG-R15 of less than 20%. As for the techniques
for resection of a portal vein tumor thrombus, two types
of procedures have been reported. One is resection of the
involved segment of the portal vein; Wu et al. insisted on
the surgical margin being secured by this technique [33].
The other is the peeling-oﬀ technique, in which a portal
venotomy is placed and the tumor thrombus is detached and
removedfromtheinternal wallofthe portal vein. Inoueetal.
showed comparable postoperative overall and recurrence-
free survivals between this peeling-oﬀ technique and the en
blocportalveinresection(5-yearoverallsurvival:39%versus
41%, P = .90; 5-year recurrence-free survival: 23% versus
18%, P = .89) [37].
As compared to portal venous invasion, HCC invasion
of the bile duct or inferior vena cava is quite rare. In regard
to the prognostic inﬂuence of bile duct tumor thrombi,
Satoh et al. previously reported that there was no signiﬁcant
diﬀerence in the postoperative prognosis between patients
withandwithoutbileductthrombi[39].However,thisresult
seemed to be inﬂuenced by the small number of patients
with bile duct thrombi. More recently, Noda et al. reported
the results of surgical resection of 22 patients with biliary
tumor thrombi; they reported a 3-year survival rate of 30%,
which was signiﬁcantly worse than that of patients without
biliary tumor thrombi. In the present study, portal or hepatic
vein tumor thrombi, seen in 13 patients (59%), was the
only signiﬁcant predictor of the prognosis [40]. Ikenaga et
al. showed that bile duct invasion was associated with a
worse prognosis irrespective of the degree of invasion, that
is, patients with biliary invasion only to a third-order or
more peripheral branch showed a similarly poor prognosis
to those with more proximal bile duct invasion (ﬁrst- or
second-order branches or the common hepatic duct) [41].
Most of these studies advocated aggressive hepatic resection
in selected HCC patients with macroscopic vasculobiliary
invasion; however, additional preoperative or adjuvant treat-
ments should be considered to improve the long-term
outcomes.
2.3.ResectionofExtrahepaticMetastases. Poonetal.reported
limited beneﬁt of aggressive resection of extrahepatic metas-
tases when the extrahepatic lesion was solitary and/or
the intrahepatic recurrence was well controlled [42]. Yang
et al. reported that extrahepatic recurrence occurring after
repetitive treatment for intrahepatic recurrence was associ-
ated with a better prognosis than simultaneous intrahepatic
and extrahepatic recurrence or extrahepatic recurrence pre-
ceding intrahepatic recurrence; however, the 5-year survival
rate after initial hepatic resection in 20 patients with the
former type of extrahepatic recurrence was only 30% [43].
The lungs are the most common site of extrahepatic
metastasis from HCC, with pulmonary metastases account-
ing for 50–60% of all extrahepatic metastases [44, 45].
The outcomes of surgical resection of lung metastases have
been increasingly reported recently, with the reported 5-year
survival rate after pulmonary resection being in the range
of 27–33%; however, the number of patients included in
each of these studies was small (8–61 patients), because, in
most cases of pulmonary metastases, the lesions are multiple
and surgical resection is contraindicated [46–49]. Kawamura
et al. suggested that surgical resection may be considered in
patients with up to three pulmonary lesions [49]. Kuo et al.
showed that the disease-free interval and number of lesions
were associated with the prognosis [47].
Surgical resection of other sites than the lung is
reported only sporadically. Recently, Chan et al. reported
the outcomes of surgical resection of extrahepatic metastases
including in the lung, bone, brain, soft tissues, and heart
and showed that resection of lung metastases was associated
with the most favorable prognosis. Although the outcomes
of resection of bone or brain metastases were dismal, with
a3 - y e a rs u r v i v a lr a t eo f9 %a n d0 % ,r e s p e c t i v e l y ,e v e n
in these groups, patients who underwent surgical resection
showed better survivals than patients who did not undergo
surgical resection [50]. Sakamoto et al. reported four cases
of resection of adrenal metastases. A literature review of 79
cases of adrenal metastases did not reveal any signiﬁcant
survival beneﬁt of surgical resection. However, considering
the risk of tumor rupture and venous invasion resulting in
pulmonary embolism, or the technical diﬃculty of TACE
due to the presence of three arteries feeding the adrenal
grand, adrenalectomy may be a valid strategy, because
it can be performed safely with minimal mortality [51].
Until other treatment alternatives are established to improve
the patients’ quality of life and life expectancy, surgical
resection may be justiﬁed for the treatment of extrahepatic
metastases.
3. Anatomic Resection
As described above, HCCs show a high predilection for
invading the adjacent portal vein and, consequently, intra-
hepatic metastasis. On the other hand, extensive hepatic
resection is contraindicated in most cases due to the severity
of the background liver disease. To overcome this problem,
Makuuchi et al. proposed anatomic subsegmentectomy [52].
In this type of hepatectomy, intraoperative ultrasonography
is performed to identify the locations of the hepatic tumors.
Dye (indigo carmine) is injected into the portal venous
tributaries supplying the region containing the tumor.
The area showing positive staining is then marked with
electrocautery, and a parenchymal transection is performed.4 International Journal of Hepatology
According to the location or size of the tumor and the
background liverfunction,a partofone Couinaud’s segment
or more than one segment is resected. The inﬂuence of
anatomic resection on the postoperative prognosis has been
evaluated recently. Most studies have shown the superiority
of anatomic resection for prolonged overall or recurrence-
free survival, especially in selected patients with solitary
HCCs, small HCCs, or HCCs fulﬁlling the Milan criteria
[14, 53–57]. Among the studies, the largest series was a
Japanese nationwide survey including 5781 patients who
underwent anatomic subsegmentectomy or nonanatomic
minor hepatectomy for solitary HCCs. The overall survival
was marginally better in the anatomic resection group in
the overall analysis (P = .053). Subgroup analysis showed
signiﬁcantly better disease-free survival following anatomic
resection in patients with HCCs measuring 2 to 5cm in
diameter (P = .0005) [56].
4.Resection of RecurrentHCCs
The most common site of recurrence is the remnant liver,
which accounts for 85% to 90% of the initial recurrences
[58]. The reported incidence of intrahepatic recurrence
within 2 years after primary hepatic resection is 70%
[58]. The eﬀectiveness of systemic chemotherapy for HCCs
has not yet been established; therefore, in the absence of
extrahepatic metastases, local treatment is currently the
only approach that can yield long-term survival in patients
with recurrent HCC. Several studies have demonstrated that
repeat hepatectomy yields a better prognosis than other non-
surgical treatments, with a 5-year survival rate after repeat
hepatectomyofaround50–70%,whichisalmostcomparable
to the survival rate after ﬁrst hepatectomy [59–63]. Wu
et al. reviewed the outcomes of patients who underwent
hepatectomy for HCC up to four times and showed that
patients undergoing their second and third hepatectomies,
but not those undergoing the fourth hepatectomy, showed
signiﬁcantly better survivals than those who did not undergo
repeat hepatectomy [64]. All of these studies, however, were
retrospective in nature, and the selection bias for patients
who underwent repeat hepatic resection must be considered.
Repeat hepatic resection is indicated for only a limited
proportion of patients, because multiple intrahepatic tumor
recurrences and/or impaired liver function due mostly to
the background liver diseases represent contraindications to
repeat hepatectomy. Minagawa et al. analyzed the prognostic
predictors in patients undergoing repeat hepatectomy and
reported a solitary HCC at primary hepatectomy, disease-
free interval of 1 year or more, and absence of portal venous
invasion at the second hepatectomy as independent predic-
tors of a favorable prognosis [65]. Repeating locoregional
treatment such as ethanol injection (PEI), radiofrequency
ablation (RFA), or TACE, for an intrahepatic recurrence
may also help in prolonging patient survival [66–70].
Locoregional treatments may be repeated as long as there are
no extrahepatic recurrences and the remnant liver function
is reasonably adequate. Surgical resection after PEI/RFA can
also be considered for recurrent HCC [71].
5.PreoperativeandAdjuvantTreatments
Unlike the case for colorectal liver metastases, in which
preoperative chemotherapy may improve the prognosis
of patients with either resectable or initially unresectable
tumors [72–75], there is no established preoperative adju-
vant strategy to improve the prognosis in HCC patients.
Previous studies have evaluated the role of preoperative
TACE, but the long-term outcomes remain controversial.
Most studies, including one RCT, have shown no survival
beneﬁt [76–82]. Furthermore, some studies identiﬁed pre-
operative TACE as a predictor of extrahepatic metastasis
[83, 84] or worse survival [79, 85]. On the other hand,
selected patients with TACE-mediated complete necrosis
showed a signiﬁcantly more favorable prognosis afterhepatic
resection [77, 83, 85–88]. These results may be explained
by Adachi’s hypothesis that viable cancer cells are less
ﬁrmly attached and are more likely to disseminate into
the blood stream during surgical manipulation following
incomplete necrosis by TACE [86]. Considering the low
incidence of complete necrosis achieved by TACE, ranging
from 6% to 29% according to previous reports [77, 87, 88],
routine implementation of preoperative TACE may not be
recommended. Several other studies report that preoperative
TACE may improve the disease-free and overall survivals
in selected cases, such as HCC patients with macroscopic
portal venous invasion [34], advanced-stage tumors [89],
severe liver dysfunction (ICG-R15  17%) [90], or centrally
located large tumors [84]. One study showed that TACE
converted initially unresectable HCCs to resectable tumors,
yielding a 5-year survival rate of 56% [91]. Taking all the
above reports into consideration, TACE as a postoperative
adjuvant treatment seems to have a role in improving the
prognosis of patients, especially of those having advanced
HCCswithportalvenousinvasionorintrahepaticmetastases
[92, 93].
A multitargeted agent sorafenib, which exerts both
antiangiogenic and antiproliferative eﬀects, is the ﬁrst sys-
temic agent to have yielded survival beneﬁt in patients
with advanced HCCs in a phase III, randomized, placebo-
controlled trial [94]. However, the beneﬁt is limited (median
overall survival: 10.7 months versus 7.9 months) and
treatment with this drug has not yet been validated as
a preoperative or adjuvant treatment. Until date, other
modalities such as hepatic artery infusion of radionuclide
Yttrium-90 microspheres, or combined subcutaneous inter-
feron alpha and intraarterial infusion chemotherapy, seem
to be more promising strategies than sorafenib treatment
to downstage advanced HCCs, including cases with macro-
scopic portal venous invasion [95–100]. Especially, two
recent reports from Japanese groups showed a response
rate of 33–52% following combined interferon and intra-
arterial 5-ﬂuorouracil therapy in advanced HCC patients
with portal venous invasion. These results suggest further
increase in the number of candidates suitable for sur-
gical resection among patients with initially unresectable
HCCs.International Journal of Hepatology 5
6. Laparoscopic Hepatectomy
Laparoscopic liver resection was ﬁrst reported in the early
1990s for partial resection of segment 6 for a 6cm focal
nodular hyperplasia and wedge resection of segment 5 for
colorectal liver metastases [101]. Since then, the number of
reported cases of laparoscopic liver resection has increased
dramatically, especially over the last 5 years [102]. Although
some surgeons are still skeptical about the oncological
curative potential of laparoscopic surgery and evaluation of
the long-term prognosis is required to justify the minimally
invasiveapproachesforhepaticmalignancies,severalspecial-
ized centers have expanded the indications of laparoscopic
hepatectomy from benign tumors to malignant tumors,
including HCCs [103–105] and from wedge resection of the
anterolateral segments to major hepatectomy or resection
of the posterosuperior segments, such as segment 8, 7, or
1[ 106, 107]. The consensus conference by 45 experts held
in October 2008 proposed that the most suitable candidates
among HCC patients for laparoscopic hepatectomy are, in
general, those with solitary lesions measuring 5cm or less in
diameter, located in the peripheral segments. The conference
also proposed that major hepatectomy or other technically
complicated procedures should be left to experienced sur-
geons [108].
Several surgeons advocate laparoscopic resection for
HCC, especially that in a cirrhotic liver, due to its less-
invasive characteristic, because less liver mobilization is
required and the amount of intravenous ﬂuid needed is
reduced due to the minimized insensible ﬂuid loss occur-
ring during this operation as compared with that during
open liver resection. Fluid accumulation in the third space
decreases, which may be expected to be associated with a
reduced risk of prolonged postoperative accumulation of
ascites [109–112]. On the other hand, higher morbidity and
mortality have been reported, even from highly specialized
institutions [113]. As for the survival outcomes, only a few
reportsbasedonstudiesofasmallnumberofcaseseachhave
been published, which have shown a comparable short-term
prognosis in patients undergoing laparoscopic hepatectomy
as compared to that in patients undergoing open hepatec-
tomy [109, 111, 112]; further investigation is required for
validation. A signiﬁcant learning curve is inevitable to estab-
lish the safety and feasibility of laparoscopic surgery [114]
and this is one of the major limitations in relation to the
popularization of laparoscopic hepatectomy. The indications
for laparoscopic resection should be appropriately decided
according to the types and conditions of the tumors and the
technical skills of the surgeons. More importantly, the safety
andoncologicalcurativepotentialmustbeaccordedpriority;
therefore, conversion to an open procedure should be
expedited if bleeding cannot be controlled laparoscopically,
or an adequate resection margin cannot be obtained, or
adhesions preclude the laparoscopic procedure [102, 113].
7. LiverTransplantation for HCCs
The Milan criteria, which were published in 1996 [14], have
servedasappropriateselectioncriteriaforpatientswithHCC
who are potential candidates for liver transplantation. The
criteriahavebeenvalidatedbynumeroussubsequentstudies,
with patients fulﬁlling the Milan criteria showing signiﬁ-
cantly better survivals than those not fulﬁlling the criteria,
in both cadaveric and living donor liver transplantation (3-
year survival rate of 79–91% versus 60–66%) [115, 116].
The criteria are also utilized by the United Network for
Organ Sharing [117]. However, the Milan criteria are rather
restrictive, permitting liver transplantation in only a limited
proportion of patients with HCC, and therefore, expansion
of the criteria has been proposed. The most representative
example of such expanded criteria is the University of San
Francisco (UCSF) criteria proposed by Yao et al., which
include solitary tumor  6.5cm, or two or three nodules
with the largest lesion  4.5cm and total tumor diameter 
8cm[118]. These criteria were also validated by subsequent
studies from high-volume transplantation centers, which
reported overall 5-year survival rates of 52–64% [119, 120].
In cases of living donor liver transplantation, it may be
possibletoexpandtheselectioncriteriamorereadily,because
the donors would be expected to have a stronger motivation
for self-giving and dedication to the recipients. In The
University of Tokyo, patients with HCC having up to 5
nodules with a maximal diameter of 5cm (the 5-5 rule) have
been treated by transplantation, and the 5-year survival rate
in a series of 72 patients treated according to this 5-5 rule
was reported to be 75% [121]. Other Japanese institutions
have reported a more aggressive approach to living donor
liver transplantation, operating on HCC patients with no
extrahepatic metastases or macroscopic vascular invasion,
but regardless of the size and number of tumors [122–124].
Soejima et al. have insisted that patients with small multiple
HCCs should be included as candidates for LT [122]. In
their report of 60 HCC patients who underwent living
donor liver transplantation, 23 patients with 4 to 10 tumors
and 12 patients with more than 10 tumors showed 3-year
recurrence-free survival rates of 75% and 72%, respectively,
and only preoperative des-gamma-carboxy prothrombin
(DCP) levels of >300mAU/ml and tumor size >5cmwere
identiﬁed as independent prognostic factors. They validated
this result recently in an extended series of 90 patients. In
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patients meeting the criteria of a maximal tumor size of
less than 5cm or DCP level of less than 300mAU/ml [124].
Similarly, Ito et al. analyzed the prognostic factors in their
series of 125 patients and proposed the following criteria: 10
or fewer tumors, with each tumor measuring 5cm or less in
diameter, and a DCP level of 400mAU/ml or less. The 5-year
survival rate in 78 patients meeting these criteria was 87%
[123].
In most Western countries as in Japan, hepatitis C virus
(HCV) is the most common etiological agent associated
with HCC. Hepatitis C recurs inevitably in the transplanted
liver, and progression to graft cirrhosis occurs more rapidly
under immunsuppression [125], which becomes another
possible cause of the patients’ death in addition to tumor
recurrence. Therefore, a special postoperative immunosup-
pression protocol, such as a steroid-free protocol [126, 127],
orcyclosporine-based instead ofatacrolimus-basedprotocol6 International Journal of Hepatology
should be considered [128]. Preemptive antiviral therapy
usinginterferonandribavirinmayalsohelpinimprovingthe
survival of the recipients, by reducing the risk of progression
of ﬁbrosis in the grafts [129, 130].
Under the current circumstance of shortage of donors,
opportunities for liver transplantation are limited. There-
fore, nontransplant treatments, including open or laparo-
scopic hepatic resection, PEI/RFA, or TACE, should be
the treatment modalities of ﬁrst choice in HCC patients
with compensated liver cirrhosis. Even in patients with
decompensated cirrhosis, these modalities may well be used
as a bridge to transplantation. Several studies have shown
that secondary or salvage transplantation for downstaged
HCC by nontransplant treatment or for recurrent HCC after
initial treatment results in acceptable survival outcomes,
especially if the HCC meets the Milan criteria prior to
transplantation [131–134]. The reported 5-year survival
rates after secondary transplantation from these studies are
in the range of 60–80%. Interestingly, Takada et al. reported
that patients with one or two non-transplant treatments
prior to liver transplantation showed better outcomes after
transplantation than patients without any previous treat-
ment and also patients with 3 or more treatments. They
concluded that patients developing recurrent HCCs should
be referred for transplantation before further nontransplant
treatment is repeated [135]. Further investigation is required
to determine the appropriate timing of transplantation.
8. Conclusions
The indications for surgical resection in patients with HCC
have expanded concomitantly with the establishment of the
safety and feasibility of aggressive resection. However, a high
incidence of postoperative recurrence is still an obstacle to
the achievement of long-term survival in advanced HCC
patients. A multimodality approach is required, especially
for patients with recurrent HCC or HCC with background
liver cirrhosis, which preclude hepatic resection. The beneﬁt
of systemic chemotherapy for extrahepatic metastases is still
limited, and the development of better pharmacological
agents in the future is expected. Most studies referred to in
this paper were retrospective in nature. Although RCTs may
not be ethically appropriate in all clinical researches, more
prospectivestudiesareneededtoaccumulateevidenceforthe
establishment of multidisciplinary treatments for HCC.
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